Delcath Systems, Inc. (DCTH)
$
8.97
-0.16 (-1.78%)
Key metrics
Financial statements
Free cash flow per share
0.5753
Market cap
311.7 Million
Price to sales ratio
3.6568
Debt to equity
0.0084
Current ratio
10.9160
Income quality
8.3393
Average inventory
10.5 Million
ROE
0.0263
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Delcath Systems, Inc., an interventional oncology company specializing in the treatment of primary and metastatic liver cancers in the U.S. and Europe, reported a net total of other income and expenses of $2,850,000.00 reflecting its non-core financial activities. The company incurred an interest expense of $0.00 highlighting its debt servicing obligations. Its operating expenses amounted to $72,774,000.00 encompassing a variety of operational costs the company has incurred throughout its fiscal activities. Delcath achieved a revenue of $85,231,000.00 underscoring its focus on a niche market within the oncology therapeutic landscape. Furthermore, the earnings per share (EPS) is reported at $0.08 indicating the company's profitability on a per-share basis and demonstrating its financial performance amidst its specialized operational focus. The clinical development program for its lead product candidate, HEPZATO KIT, involves the FOCUS clinical trial targeting metastatic hepatic dominant Uveal Melanoma to assess the objective response rate, while also offering HEPZATO as the standalone CHEMOSAT Hepatic Delivery System in Europe for various liver cancer treatments. In terms of investment perspective, the stock is affordable at $11.54 making it suitable for budget-conscious investors. However, the stock has a low average trading volume of 479,874.00 indicating lower market activity that might affect liquidity. Delcath’s market capitalization stands at $311,673,297.00 classifying the company as a small-cap player within the broader financial arena. It is a key player in the Medical - Devices industry, contributing significantly to the overall market landscape with its innovative approaches to cancer treatment. Additionally, it belongs to the Healthcare sector, driving not only its own growth but also fostering advancements that may benefit the healthcare industry as a whole.
Is Delcath Systems, Inc. (DCTH) a good investment?
Investing in Delcath Systems, Inc. (DCTH) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is Delcath Systems, Inc. (DCTH)'s stock forecast?
Analysts predict Delcath Systems, Inc. stock to fluctuate between $8.12 (low) and $18.23 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Delcath Systems, Inc.'s market capitalization?
As of 2026-03-27, Delcath Systems, Inc.'s market cap is $311,673,297, based on 34,746,187 outstanding shares.
How does Delcath Systems, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Delcath Systems, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Delcath Systems, Inc. (DCTH) stock?
To buy Delcath Systems, Inc. (DCTH) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DCTH. Place an order (Market, Limit, etc.).
What is the best time to invest in Delcath Systems, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Delcath Systems, Inc. stock ever split?
Delcath Systems, Inc.'s last stock split was 1:700 on 2019-12-24.
How did Delcath Systems, Inc. perform in the last earnings report?
Revenue: $85,231,000 | EPS: $0.08 | Growth: -108.15%.
Where can I find Delcath Systems, Inc.'s investor relations reports?
Visit https://www.delcath.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Delcath Systems, Inc.?
You can explore historical data from here
What is the all-time high and low for Delcath Systems, Inc. stock?
All-time high: $18.23 (2025-05-20) | All-time low: $2.25 (2023-11-14).
What are the key trends affecting Delcath Systems, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Delcath Systems, Inc.'s revenue remains under pressure due to weak patient starts in the third quarter of 2025. The fundamentals of the company remain intact, though, and 2026 should be another year of strong growth. Delcath's profitability will be under pressure due to investments in clinical trials and sales and marketing.
defenseworld.net
Delcath Systems (NASDAQ: DCTH) reported record results for 2025 and outlined a commercial and clinical roadmap that management believes can support continued growth, emphasizing expanding treatment-center capacity, increasing new patient starts, and strengthening referral networks. On the company's fourth-quarter and year-end 2025 earnings call, executives also provided 2026 revenue guidance of at least $100 million and
seekingalpha.com
Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript
seekingalpha.com
Delcath Systems is upgraded from Hold to Buy as sales stabilize and insider confidence grows. DCTH expects to hit the upper end of 2025 guidance at $85M, signaling operational stabilization after earlier guidance cuts. CHOPIN trial results expand HEPZATO's potential beyond liver therapies, supporting a broader market opportunity.
businesswire.com
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results and business updates for the fourth quarter and year-ended December 31, 2025. Preliminary Fourth Quarter and Full-Year 2025 Financial Results (unaudited) Total fourth quarter and full year revenue expected to be approximately $20.7 million and.
businesswire.com
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from subgroup analyses of the phase 3 FOCUS study. The publication, titled “Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma” was published in the Journal of Cancer.
businesswire.com
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results from a retrospective analysis conducted by researchers at the University of Tubingen, Germany. The study, titled “Characterization of long-term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021,” was published in the In.
seekingalpha.com
Delcath's third quarter was weak due to seasonality and pricing headwinds, but data suggests these are temporary challenges. Delcath continues to expand its treatment sites and sales force, which should lead to strong growth in 2026. Clinical trials to expand the company's addressable market are also now under way, which could provide enormous upside in several years time.
seekingalpha.com
Delcath Systems, Inc. ( DCTH ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO & Director Sandra Pennell - Chief Financial Officer Vojislav Vukovic - Chief Medical Officer Conference Call Participants Marie Thibault - BTIG, LLC, Research Division John Newman - Canaccord Genuity Corp., Research Division Jake Soucheray Kesav Chandrasekhar Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Yale Jen Bill Maughan Presentation Operator ” David Hoffman General Counsel, Corporate Secretary & Chief Compliance Officer ” Gerard Michel CEO & Director ” Sandra Pennell Chief Financial Officer ” Vojislav Vukovic Chief Medical Officer ” Marie Thibault BTIG, LLC, Research Division ” BTIG, LLC, Research Division John Newman Canaccord Genuity Corp., Research Division ” Canaccord Genuity Corp., Research Division Jake Soucheray ” Craig-Hallum Capital Group LLC, Research Division Kesav Chandrasekhar ” Stephens Inc., Research Division Swayampakula Ramakanth H.C.
businesswire.com
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 4, 2025, at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Tuesday, November.
See all news
